Trade

with

Supernus Pharmaceuticals Inc
(NASDAQ: SUPN)
AdChoices
7.84
+0.04
+0.51%
After Hours :
7.84
0.00
0.00%

Open

7.78

Previous Close

7.80

Volume (Avg)

193.65k (420.88k)

Day's Range

7.68-7.99

52Wk Range

5.95-11.47

Market Cap.

336.50M

Dividend Rate ( Yield )

-

Beta

1.56

Shares Outstanding

42.92M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 12.02M

    • Net Income

    • -92.27M

    • Market Cap.

    • 336.50M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -116.88

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.56

    • Forward P/E

    • -

    • Price/Sales

    • 5.79

    • Price/Book Value

    • 10.08

    • Price/Cash flow

    • -5.68

      • EBITDA

      • -83.68M

      • Return on Capital %

      • -52.04

      • Return on Equity %

      • -169.92

      • Return on Assets %

      • -52.04

      • Book Value/Share

      • 0.78

      • Shares Outstanding

      • 42.92M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10,460.50

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 6.22

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 93.53

            • 64.72

            • Pre-Tax Margin

            • -116.88

            • 13.77

            • Net Profit Margin

            • -116.88

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 98.20

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 397.20

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.86

              • 0.33

              • Current Ratio

              • 3.75

              • 1.52

              • Quick Ratio

              • 3.06

              • 0.87

              • Interest Coverage

              • -6.89

              • 6.77

              • Leverage Ratio

              • 2.82

              • 1.91

              • Book Value/Share

              • 0.78

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.93

                • 63.69

                • P/E Ratio 5-Year High

                • -10.55

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.72

                • 19.71

                • Price/Sales Ratio

                • 5.76

                • 3.64

                • Price/Book Value

                • 10.02

                • 3.39

                • Price/Cash Flow Ratio

                • -5.68

                • 21.79

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -169.92

                    (-)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -52.04

                    (-24.80)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -65.44

                    (-)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 0.45

                  • 1.80

                  • Asset Turnover

                  • 0.45

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -61.92M
                  Operating Margin
                  -515.18
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.68
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  101.62%

                  Mutual Fund Ownership

                  21.99%

                  Float

                  60.17%

                  5% / Insider Ownership

                  1.56%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,549,200

                  • -27.72

                  • 3.68

                  • T. Rowe Price New Horizons Fund

                  •  

                    1,218,900

                  • -2.10

                  • 2.89

                  • Columbia Small Cap Core Fund

                  •  

                    688,656

                  • 0.00

                  • 1.60

                  • Worldwide Healthcare

                  •  

                    580,000

                  • 0.00

                  • 1.38

                  • iShares Nasdaq Biotechnology

                  •  

                    559,224

                  • -1.85

                  • 1.17

                  • Vanguard Total Stock Mkt Idx

                  •  

                    465,212

                  • 0.00

                  • 1.08

                  • iShares Russell 2000 (AU)

                  •  

                    458,045

                  • -0.90

                  • 0.96

                  • Columbia Small Cap Value Fund I

                  •  

                    380,836

                  • 0.00

                  • 0.89

                  • Mutual of America Small Cap Growth

                  •  

                    355,272

                  • -19.57

                  • 0.84

                  • Mutual of America Small Cap Value

                  •  

                    325,058

                  • -26.28

                  • 0.77

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • NEA Management Company, LLC

                  •  

                    10,650,000

                  • 0.00%

                  • 25.04

                  • Abingworth LLP

                  •  

                    3,600,000

                  • 0.00%

                  • 8.53

                  • Abingworth Management Ltd

                  •  

                    3,277,869

                  • -8.95%

                  • 7.64

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,815,530

                  • -6.20%

                  • 6.56

                  • Discovery Group I, Llc

                  •  

                    2,785,153

                  • +21.01%

                  • 6.49

                  • Ardsley Advisory Partners

                  •  

                    1,765,000

                  • +11.01%

                  • 4.19

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    1,732,581

                  • -6.72%

                  • 4.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  -

                  Supernus Pharmaceuticals Inc., was incorporated in Delaware on March 30, 2005. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, includin...moreg neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market. The Company has a broad portfolio of drug development technologies consisting of six platforms that include the following: Microtrol, Solutrol (matrix delivery platform) and EnSoTrol. In addition to Oxtellar XR and Trokendi XR, the Company’s proprietary technologies have been used in the following approved products: Carbatro...morel, Adderall XR, and Intuniv, marketed by Shire; Equetro, marketed by Validus Pharmaceuticals Inc.; Sanctura XR, marketed by Allergan, Inc.; Oracea, marketed by Galderma Laboratories, L.P.; and Orenitram. Oxtellar XR and Trokendi XR are novel extended release formulations of two well known and approved AEDs, oxcarbazepine and topiramate. The Company’s psychiatry portfolio includes three product candidates for the treatment of impulsive aggression in patients with ADHD, ADHD or its coexisting conditions and one product candidate for depression, each of which is designed to bring important advancements in therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.lessless

                  Key People

                  Jack Khattar

                  CEO/Director/President/Secretary

                  Dr. M. James Barrett,PhD

                  Chairman of the Board/Director

                  Gregory S. Patrick

                  CFO/Chief Accounting Officer/Vice President

                  Dr. Stefan K.F. Schwabe, M.D., Ph.D.

                  Chief Medical Officer/Executive VP, Divisional

                  Jones W. Bryan

                  Vice President, Divisional

                  • Supernus Pharmaceuticals Inc

                  • 1550 East Gude Drive

                  • Rockville, MD 20850

                  • USA.Map

                  • Phone: +1 301 838-2500

                  • Fax: -

                  • supernus.com

                  Incorporated

                  2005

                  Employees

                  235

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: